HealthDay - TUESDAY, Oct. 30 (HealthDay News) -- An experimental drug calledaxitinib shows promise for treating people with what's known ascytokine-refractory metastatic kidney cancer -- a group of patients whotypically have a poor response to drug treatment.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.